Fennec Pharmaceuticals Profit Margin

The latest profit margin for FENC is -6.2% as of June 2026. That compares with -35.05% in the prior-year period — up 82.3% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Fennec Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, FENC's profit margin moved from -35.05% to -6.2% — a 82.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fennec Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, FENC currently prints -6.2% for profit margin, while the sector average sits near 21.34%. That is roughly 129.1% below the sector mean. Large gaps often invite a closer look at Fennec Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Fennec Pharmaceuticals converts resources into returns. At -6.2%, FENC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -35.05% in the prior-year period — up 82.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FENC's profit margin (-6.2%), review year-over-year change from -35.05%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.